Liquidia (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Technologies, Inc. is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH). LIQ861 aims to offer a more convenient and potentially more consistent dosing approach compared with current liquid-based nebulized therapies. Besides PAH, Liquidia is exploring additional indications and dosage forms to expand the use of its PRINT platform, including collaborations focused on vaccine adjuvants and other respiratory applications.

Liquidia Technologies was founded to translate advanced particle-engineering science into therapeutic benefit and has assembled a team with experience in respiratory drug development, regulatory affairs and clinical operations. The company conducts clinical research primarily in the United States, and it plans to pursue regulatory filings in major markets following the completion of pivotal studies. Under the leadership of President and CEO Chris Critelli, Liquidia continues to advance its pipeline toward potential commercialization.

Key Stats

• Today's Range: $38.50 to $40.46
• 50-Day Range: $30.00 to $41.40
• 52-Week Range: $11.85 to $46.67
• Volume: 1.06 million shs
• Average Volume: 1.64 million shs
• Market Capitalization: $3.57 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.44
• Consensus Rating: Moderate Buy

Liquidia Stock Analysis - MarketRank™

Liquidia scored higher than 51% of companies evaluated by MarketBeat, and ranked 431st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Liquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.

Upside/Downside

The consensus price target for Liquidia is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Liquidia has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 66.29%

Earnings Growth

Earnings for Liquidia are expected to grow by 66.29% in the coming year, from $1.75 to $2.91 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia is -48.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia is -48.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Liquidia has a P/B Ratio of 78.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.63% of the float of Liquidia has been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 11.29, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia has recently decreased by 3.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia does not currently pay a dividend.

Dividend Growth

Liquidia does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.59

News Sentiment

Liquidia has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Liquidia this week, compared to 6 articles on an average week.

Search Interest

Only 12 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Liquidia to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,746,258.00 in company stock.

Percentage Held by Insiders

26.50% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LQDA Stock Analysis - Frequently Asked Questions

How have LQDA shares performed this year?

Liquidia's stock was trading at $34.49 at the beginning of 2026. Since then, LQDA stock has increased by 16.4% and is now trading at $40.13.

How were Liquidia's earnings last quarter?

Liquidia Corporation (NASDAQ:LQDA) issued its earnings results on Thursday, March, 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm's revenue for the quarter was up 3072.4% compared to the same quarter last year.
Read the conference call transcript.

When did Liquidia IPO?

Liquidia (LQDA) raised $50 million in an IPO on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia's major shareholders?

Top institutional shareholders of Liquidia include Capricorn Fund Managers Ltd (0.28%), Bank of New York Mellon Corp (0.22%), LGT Fund Management Co Ltd. (0.12%) and Sigma Planning Corp (0.07%). Insiders that own company stock include Caligan Partners Lp, Stephen M Bloch, Roger Jeffs, Russell Schundler, Paul B Manning, Michael Kaseta, Jason Adair, Robert A Lippe, Scott Moomaw, Dana Boyle, Rajeev Saggar, Sarah Krepp and Raman Singh.
View institutional ownership trends.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Liquidia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liquidia investors own include JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Ford Motor (F), Predictive Oncology (POAI), Tesla (TSLA), Advanced Micro Devices (AMD) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LQDA
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 50
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Liquidia: $43.44
• High Price Target: $55.00
• Low Price Target: $19.00
• Potential Upside/Downside: +8.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 22.93
• P/E Growth: N/A
• Net Income: -$68.92 million
• Net Margins: -43.53%
• Pretax Margin: -43.53%
• Return on Equity: -209.33%
• Return on Assets: -25.32%

Debt

• Debt-to-Equity Ratio: 2.97
• Current Ratio: 2.01
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: $158.32 million
• Price / Sales: 22.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 78.69

Miscellaneous

• Outstanding Shares: 88,894,000
• Free Float: 66,137,000
• Market Cap: $3.57 billion
• Optionable: Optionable
• Beta: 0.41